Biotech · Private company · San Diego, CA, US
Vivreon Biosciences, LLC
Track this companyFree. Adds Vivreon Biosciences, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards8
- Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's DiseaseFiscal year 2026 · $1.9MNIH RePORTER 5SB1AG087756-02 · fetched Nov 12, 2026
- Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's DiseaseFiscal year 2025 · $2MNIH RePORTER 1SB1AG087756-01A1 · fetched Nov 12, 2026
- Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative ColitisFiscal year 2025 · $1MNIH RePORTER 5R44AI165096-03 · fetched Nov 12, 2026
- Development of a Novel Calcium Channel Therapeutic for Opioid Use DisorderFiscal year 2025 · $1.1MNIH RePORTER 5R44DA058467-03 · fetched Nov 12, 2026
- Development of a Novel Calcium Channel Therapeutic for DystrophinopathiesFiscal year 2024 · $306.9KNIH RePORTER 1R43AR083315-01A1 · fetched Nov 12, 2026
- Predevelopment of VV8220, a Gut-selective CRAC Channel Therapeutic for Ulcerative ColitisFiscal year 2024 · $1MNIH RePORTER 2R44AI165096-02 · fetched Nov 12, 2026
- Development of a Novel Calcium Channel Therapeutic for Opioid Use DisorderFiscal year 2024 · $1.4MNIH RePORTER 4R44DA058467-02 · fetched Nov 12, 2026
- IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor ImmunotherapyFiscal year 2024 · $502KNIH RePORTER 5R44CA268541-02 · fetched Nov 12, 2026